UroGen Pharma Ltd. Files 8-K: Material Agreement & Equity Sales
Ticker: URGN · Form: 8-K · Filed: Feb 20, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, sec-filing
TL;DR
UroGen Pharma inked a big deal and sold some stock on Feb 14th.
AI Summary
UroGen Pharma Ltd. announced on February 14, 2025, that it entered into a material definitive agreement and also reported unregistered sales of equity securities. The company is incorporated in Israel and its principal executive offices are located in Princeton, New Jersey.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing mentions both a material definitive agreement and unregistered sales of equity, which can introduce complexities and potential risks related to financing and shareholder dilution.
Key Numbers
- 001-38079 — SEC File Number (Identifies UroGen Pharma's filing with the SEC.)
- 98-1460746 — IRS Employer Identification No. (UroGen Pharma's tax identification number.)
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- February 14, 2025 (date) — Date of earliest event reported
- Princeton, New Jersey (location) — Address of principal executive offices
- Israel (location) — State or other jurisdiction of incorporation
FAQ
What is the nature of the material definitive agreement entered into by UroGen Pharma Ltd. on February 14, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into on February 14, 2025.
What were the terms of the unregistered sales of equity securities by UroGen Pharma Ltd. on February 14, 2025?
The filing reports unregistered sales of equity securities but does not provide specific details regarding the terms, price, or amount of these sales.
Where are UroGen Pharma Ltd.'s principal executive offices located?
UroGen Pharma Ltd.'s principal executive offices are located at 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
In which jurisdiction is UroGen Pharma Ltd. incorporated?
UroGen Pharma Ltd. is incorporated in Israel.
What is the standard industrial classification for UroGen Pharma Ltd.?
The standard industrial classification for UroGen Pharma Ltd. is Pharmaceutical Preparations [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding UroGen Pharma Ltd. (URGN).